Research On Improvement Of Internal Control Of Pharmaceutical Enterprises Under The New COSO-ERM Framework

After decades of exploration and research,the concept and practice of enterprise internal control have made great development and progress in practice.However,with the rapid development and changes in China and the world market economy,stakeholders have paid more attention to the internal control and risk factors of pharmaceutical companies."Enterprise Risk Management-Strategic and Performance Integration Framework"(COSO-ERM 2017)provides a new risk management concept and framework for the work of various departments of Chinese pharmaceutical companies.During the continuous research and brewing of COSO-ERM(2017),the State Food and Drug Administration and the China Securities Regulatory Commission jointly issued a report,accusing Kangmei Pharmaceutical,one of China's largest pharmaceutical leading companies,previously disclosed 2016-2018 The annual financial report and other information are seriously false,and Kangmei Pharmaceutical's internal control has encountered huge problems.Under such circumstances,a comprehensive analysis of this representative case was conducted to study the internal control issues that have occurred in China's larger pharmaceutical companies in recent years,and the internal of Chinese pharmaceutical companies based on COSO-ERM(2017)was proposed.The control defect improvement plan is of great significance for further enriching the internal control theory,realizing the added value of the company's economic benefits,and ensuring the safety of the people and the people's medication.First,this article briefly introduces the main technical background of the current paper and the research framework of the paper,and summarizes the characteristics of the internal control of pharmaceutical companies and classic research results.Secondly,it briefly analyzes the development and reform of internal control in modern pharmaceutical enterprises and the general principles and defects of internal control in pharmaceutical processes.Then,from the characteristics and perspectives of the internal control of pharmaceutical companies,some outstanding problems in the construction of the internal control framework system of Kangmei Pharmaceutical were analyzed.By comparing the enterprise risk management frameworks of 2004 and 2017 in two periods,it summarizes and puts forward the necessity of strengthening and implementing the new version of the COSO enterprise risk management framework in order to improve the internal control of pharmaceutical companies.At the same time,it puts forward the general basic principles and objectives of pharmaceutical companies to improve the internal control framework system.Through the integration of the relevant specific content of internal control elements,suggestions and suggestions for improving the internal control of China's pharmaceutical companies are put forward.Finally,the research results of this paper are analyzed and summarized,and the future development direction and prospects of internal control research are well prospected.